Ixabepilone in Treating Young Patients With Refractory Solid Tumors

This study has been completed.

Study NCT00331643 Information provided by National Cancer Institute (NCI)

First Received: May 30, 2006 Last Updated: November 20, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Publications:

Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010 Jan 15;16(2):750-4. Epub 2010 Jan 12.

Jacobs S, Fox B, Krailo MD, et al.: Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. [Abstract] J Clin Oncol 26 (Suppl 15): A-10026, 2008.